esketamine
Articles tagged with “esketamine”
CBT After Esketamine Cuts Relapse Risk, Trial Finds
The CBT-ENDURE trial shows 16 weeks of CBT after esketamine significantly reduces relapse risk and suicidal ideation. What it means for ketamine patients.
Esketamine Safety Protocols: What Clinicians Now Emphasize
A new clinical overview on esketamine nasal spray details REMS requirements, two-hour monitoring, and vitals tracking. Here's what it means for ketamine patients.
When to Switch or Stay: NMDA Therapy Discontinuation Rates
New analysis reveals why patients stop NMDA receptor antagonist therapy—and what discontinuation data means for low-dose ketamine monitoring and dosing decisions.
What Dropout Rates Reveal About NMDA Therapy Tolerability
New psychiatric guidance examines why patients stop NMDA antagonist therapy and what side effect data means for low-dose ketamine treatment decisions.
When Ketamine Side Effects Signal Time to Adjust Dose
New clinical analysis examines why patients stop NMDA antagonist therapy—and how smarter dose management may improve remission outcomes in TRD.
What Side Effect Data Tells Us About Ketamine Dosing
New analysis of NMDA receptor antagonist side effects in treatment-resistant depression underscores why dose optimization and early monitoring matter.
NMDA Antagonist Side Effects: What the Data Says
New clinical analysis examines why patients stop ketamine and esketamine treatment—and what smarter monitoring can do to keep them on track.
Ketamine Side Effects & When to Switch: New Clinical Guidance
New clinical guidance urges tracking PHQ-9 scores, monitoring side effects closely, and switching NMDA treatments sooner to reach remission faster.
NMDA Antagonist Side Effects: What the Data Now Shows
Psychiatric Times reviews side effect profiles and dropout rates for NMDA antagonists like ketamine. Here's what it means for low-dose ketamine patients.
How Clinicians Choose TRD Treatments in 2026
New clinical guidance on treatment-resistant depression highlights how patient preference, speed of response, and functional outcomes shape ketamine treatment decisions.
Esketamine's Role in Treatment-Resistant Depression
A new clinical overview examines esketamine's place in TRD care, including patient selection, access barriers, and rapid-acting benefits for suicidal ideation.
Glutamate Pathway Treatments Reshape TRD Care in 2026
A 2026 review in Psychiatric Times highlights how esketamine and glutamate-targeting drugs are changing treatment-resistant depression care.
IV Racemic Ketamine vs Esketamine (Spravato): A Clinical Comparison
Evidence-based comparison of IV racemic ketamine and intranasal esketamine (Spravato) for treatment-resistant depression, examining mechanism differences, efficacy data, FDA status, cost, access, and side effects.
Research and Clinical Evidence
Questions and answers about the scientific evidence supporting ketamine therapy, FDA approval status, landmark clinical trials, and the direction of ongoing research.
Cost-Effectiveness of Ketamine Therapy: Health Economic Evidence
Health economic analysis of ketamine therapy cost-effectiveness, examining direct treatment costs, comparative value versus alternatives, QALY gains, and payer perspectives.
Treatment-Resistant Depression Algorithms: Where Ketamine Fits
Analysis of where ketamine fits within treatment-resistant depression algorithms, reviewing staging models, sequencing strategies, and evidence-based positioning in the TRD pathway.
Telehealth Ketamine Marketing Compliance: Regulatory and Ethical Guidelines
Regulatory guide for marketing at-home ketamine therapy and esketamine services, covering FDA rules, DEA requirements, and state telemedicine laws.
Esketamine vs Racemic Ketamine Dosing: Comparative Pharmacology
Comparative pharmacology of esketamine versus racemic ketamine dosing, examining enantiomer-specific receptor binding, clinical potency differences, and dosing equivalencies.
Spravato (Esketamine) Nasal Spray Protocol and Administration Guidelines
A detailed clinical guide to the FDA-approved intranasal esketamine (Spravato) protocol, covering REMS program requirements, dosing schedules, administration procedures, and post-dose monitoring for treatment-resistant depression and major depressive disorder with suicidal ideation.
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.